Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Exelixis (Thyroid Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how the study drug (Cabozantinib) can treat a type of thyroid cancer called differentiated thyroid cancer (DTC).
What is the Condition Being Studied?
Thyroid cancer

Who Can Participate in the Study?

- Adults with a diagnosis of differentiated thyroid cancer (DTC)
- Getting thyroid suppression therapy
- Have been treated with (or cannot get) radioactive iodine before
- Have been treated with at least one VEGFR-targeting agent (such as Lenvatinib or Sorafenib) before

Age Group

What is Involved?

If you choose to join this study you will:
- Come for a clinic visit every 2 weeks for 9 weeks, then once a month
- Be randomized (like drawing numbers out of a hat) to one of 2 groups:
-- Group 1 will get the study drug (Cabozantinib)
-- Group 2 will get a placebo (harmless
-You will have a 2 out of 3 chance of being in Group 1

Study Details

Full Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy. XL184-311
Principal Investigator
Endocrine Oncologist
Protocol Number
IRB: PRO00101379
NCT: NCT03690388
Phase III
Contact the Duke Recruitment Innovation Center